Aspireo Somatoprim wins positive opinion from EMA committee for acromegaly
Somatoprim, the somatostatin analog (SSA) based on a novel amino acid composition, demonstrated significant receptor binding and pharmacological profile compared to currently marketed SSAs. Aspireo CEO Carsten Dehning
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.